Novo Nordisk A/S vs Wix.Com Ltd — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Wix.Com Ltd trades at $76.56 (market cap $3.11B). The key difference: Novo Nordisk A/S is far larger — about 53.2× Wix.Com Ltd's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Wix.Com Ltd for 62 Days on average.
| NVO | WIX | |
|---|---|---|
Market Cap | $165.31B | $3.11B |
Volume | 11,432,838 | 809,286 |
Sector | Health | Technology |
52-Week High | $63.98 | $145.54 |
52-Week Low | $35.29 | $40.43 |
Typical Hold Time | 116 Days | 62 Days |
Enterprise Value | $179.56B | $4.19B |
Dividend Yield | 4.71% | — |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
WIX stock trades at $74.13, up 1.59% today, with a neutral technical signal and bullish moving averages. Revenue grew to $1.99B in 2025, but net income margin is negative at -8.19%. The company faces a securities class action lawsuit, with multiple law firms announcing deadlines in late September 2026. Analyst consensus is a Buy with a $77.00 price target, though valuation ratios like P/E of 62.84 appear elevated.
The outlook is mixed: strong revenue growth and positive cash flow from operations support the bullish analyst stance, but legal risks and negative profitability margins pose significant headwinds. Upside depends on sustained earnings beats and resolution of litigation, while downside risks include prolonged negative margins and competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →